|Application:||Gene expression microarray analysis|
|Number of samples:||33|
|Release date:||Sep 27 2007|
|Last update date:||Dec 6 2012|
|Diseases:||Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma|
|Dataset link||Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia|
We carried out a prospective multicentric study on childhood B-ALL leukemia to elucidate the molecular processes involved in TEL/AML1-positive leukemia. All the patients included in this study received treatment according to the French FRALLE 2000 trial. We used Agilent whole-genome oligo-chips (44K-G4112A) to compare the gene expression signatures of TEL/AML1-positive patients to those of TEL/AML1-negative patients with no recurrent chimeric products irrespective of their clinical risk category. Previous microarray gene expression studies had revealed the effect of chromosomal alteration on transcription profiles, so we excluded from our cohort those patients with other recurrent chromosomal translocations or fusion transcripts (BCR/ABL, E2A/PBX1, MLL rearrangements). We then searched for the biological pathways associated with genes differentially expressed in TEL/AML1-positive leukemia (ETV6/RUNX1).
Citations per year